AMRI Names Senior Director, Analytical and Quality Services

AMRI (NASDAQ: AMRI) announced today that Junan Guo, Ph.D. has joined the company as senior director, analytical and quality services. Dr. Guo fills the role vacated by Dr. Steven Hagen, who was promoted to vice president of pharmaceutical development and manufacturing in September 2008.

Dr. Guo will oversee all domestic analytical chemistry, preformulation and formulation, quality assurance and regulatory affairs efforts, including support related to early stage discovery and preclinical development, as well as the manufacturing of clinical trial materials, intermediates, and commercial active pharmaceutical ingredients. This includes developing analytical methods to test the purity of clinical trial candidates and commercial products manufactured at AMRI. He will provide leadership to a team of over 100 skilled scientists and quality professionals, and work closely with customers.

Prior to joining AMRI, Dr. Guo was director, analytical development at Patheon. There, he managed a scientific staff of about 170 individuals at multiple locations responsible for supporting contract dosage form development and manufacturing services. He began his tenure at Patheon in 1999 in the role of supervisor, analytical development. Prior to Patheon, he worked at Genpharm, Inc. in Toronto, Canada in the areas of analytical R&D and technology transfer.

Dr. Guo earned a Ph.D. in physical organic chemistry from The University of Western Ontario. He also holds a master’s degree in medicinal chemistry from the Chinese Academy of Medical Sciences in Beijing, and a bachelor’s degree in chemistry from Beijing Normal University.

AMRI Vice President, Pharmaceutical Development and Manufacturing Steven Hagen said, "We are pleased that Dr. Guo is joining our team as he has considerable CRO experience in pharmaceutical development and he is also trained in Lean Six Sigma techniques. These experiences will greatly aid our expansion plans and efficiency efforts across the AMRI development and manufacturing spectrum.”

About AMRI

Founded in 1991, Albany Molecular Research, Inc. (AMRI) provides scientific services, products and technologies focused on improving the quality of life. AMRI works on drug discovery and development projects and conducts manufacturing of active ingredients and pharmaceutical intermediates for many of the world's leading healthcare companies. As an additional value added service to its customers, the company is also investing in R&D in order to expand its contract services and to identify novel early stage drug candidates with the goal to outlicense to a strategic partner. With locations in the U.S., Europe, and Asia, AMRI provides customers with a wide range of services, technologies and cost models.

Forward-looking Statements

Statements in this press release that are not historical facts are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve risks and uncertainties. These statements may be identified by forward-looking words such as "may," "could," "should," "would," "will," "intend," "expect," "anticipate," "believe" and "continue" or similar words. Readers should not place undue reliance on our forward-looking statements. The company's actual results may differ materially from such forward-looking statements as a result of numerous factors, some of which the company may not be able to predict and may not be within the company's control. Factors that could cause such differences include, but are not limited to the company's ability to attract and retain experienced scientists, trends in pharmaceutical and biotechnology companies outsourcing of chemical research and development, delay or denial of approvals from the FDA, the company's ability to enforce its intellectual property and technology rights, the risks posed by international operations to the company, and the company's ability to effectively manage its growth as well as those factors discussed in the company's Annual Report on Form 10-K for the year ended December 31, 2007 as filed with the Securities and Exchange Commission on March 17, 2008 and the company's other SEC filings. The company does not undertake any duty to and does not intend to update any forward-looking statements contained in this press release after the date of this press release.